Description: Relmada Therapeutics is a clinical-stage, publicly traded biotechnology company developing novel medicines that potentially address areas of high unmet medical need in the treatment of central nervous system (CNS) diseases. Relmada's lead program, dextromethadone (REL-1017), is an N-methyl-D-aspartate (NMDA) receptor antagonist. NMDA receptor antagonists may have potential in the treatment of a range of psychiatric and neurological disorders associated with a variety of cognitive, neurological and behavioral symptoms.
Home Page: www.relmada.com
RLMD Technical Analysis
2222 Ponce de Leon Boulevard
Coral Gables,
FL
33134
United States
Phone:
786 629 1376
Officers
| Name | Title |
|---|---|
| Dr. Sergio Traversa M.B.A., MBA, Pharm.D., PharmD | CEO & Director |
| Mr. Maged S. Shenouda M.B.A., MBA, R.Ph, R.Ph. | Chief Financial Officer |
| Mr. Charles S. Ence CPA, M.B.A. | Chief Accounting & Compliance Officer |
| Dr. Paolo Manfredi M.D., Ph.D. | Chief Scientific Officer |
| Ms. Gina DiGuglielmo | VP & Head of Clinical Operations |
| Dr. Marco Pappagallo M.D. | Chief Medical Officer |
| Mr. John Hixon | Head of Commercial |
| Dr. Richard M. Mangano | Consultant |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.5736 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2014-10-09 |
| Fiscal Year End: | June |
| Full Time Employees: | 10 |